Pharmaceutical

NBE Therapeutics opens ADC research facility in Switzerland

Boehringer Ingelheim subsidiary NBE Therapeutics has opened its new antibody-drug conjugates (ADC) R&D facility in Basel, Switzerland.

Apr 4, 2025 - 06:00
NBE Therapeutics opens ADC research facility in Switzerland
Boehringer Ingelheim subsidiary NBE Therapeutics has opened its new antibody-drug conjugates (ADC) R&D facility in Basel, Switzerland.
Read the original article

Tags:

Previous Article

New Sea Grant Report Aids Great Lakes Fish Farmers in Understanding Aquaculture ...

Next Article

Digital cognitive assessments and blood-based biomarkers in Alzheimer’s research

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Drug delivery innovations push forth women’s health

Drug delivery innovations push forth women’s health

Apr 11, 2024

STAT+: Pharmalittle: CRISPR pioneers reflect on future of gene editing; U.K. and pharma reach deal on how NHS pays for drugs

STAT+: Pharmalittle: CRISPR pioneers reflect on future ...

Nov 21, 2023

New lupus partnership with FDA aims to end drug trials’ history of failure

New lupus partnership with FDA aims to end drug trials’...

Mar 30, 2023